Patent 9358240 was granted and assigned to United Therapeutics on June, 2016 by the United States Patent and Trademark Office.
Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.